Dedicated Focus on Computational Kinase
Pre-Conference Short Course: Wednesday, June 14th
Designing Structure-Based Kinase Inhibitors

Conference Highlights:

• Cutting-Edge Sessions from Industry Leaders

• Hot Topic Sessions on Fragment-Based Drug Discovery NEW!

• Panel Discussion: How Much More Effective will Drug Discovery Become NEW!
   in the Next 10 Years?

• Case Studies from Abbott Laboratories and Wyeth Research NEW!

• And much more!

Hear from Industry Leaders Including:

• William L. Jorgensen, Ph.D., Whitehead Professor of Chemistry, Department of
   Chemistry, Yale University

• Dr. Mario Lobell, Computational Chemistry, Bayer HealthCare, Germany

• Klaus Müller, Ph.D., Pharmaceutical Research-Head of Science & Technology
   Relations, F. Hoffmann-La Roche Ltd.

• Mark Murcko, Ph.D., Vice President and Chief Technology Officer, Vertex
   Pharmaceuticals, Inc.

• Christopher Murray, Ph.D., Director, Computational Chemistry and Informatics,
   Astex Therapeutics

• Leszek Poppe, Ph.D., Principle Scientist, Molecular Structure Department, Amgen,
   Inc.

• Tomi K. Sawyer, Ph.D., Senior Vice President, Drug Discovery, ARIAD
   Pharmaceuticals

• Robert A. Volkmann, Ph.D., Senior Research Fellow, Pfizer Global Research and
   Development

• And many more!